Moderna's Covid-19 vaccine is 94.5% effective
November 16, 2020  19:17
image
US biotech company Moderna on Monday announced a new potential Covid-19 vaccine, which has been shown to be 94.5 per cent effective at protecting people from coronavirus, according to interim results from late-stage clinical trials.

This announcement followed announcements by US giant Pfizer and Germany's BioNTech who said their vaccine, was found to be more than 90 per cent effective.

Both shots rely on a technology called messenger RNA, which is designed to transform the body's own cells to making the vaccine.

Stephane Bancel, Moderna's chief executive termed it as a "pivotal" moment in the development of the vaccine, on which the company had been working since early this January.

"This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease," said Bancel in a statement.

Moderna also said it expected its vaccine to remain stable when refrigerated at between 2C and 8C for 30 days, significantly longer than the shot developed by BioNTech-Pfizer, which can survive in a normal fridge for only up to five days and must otherwise be stored at minus 75C.

-- ANI
« Back to LIVE

TOP STORIES